NCT05146869View on ClinicalTrials.gov

A Single-dose and Multiple-dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of DBPR108 Tablets in Type 2 Diabetes Mellitus Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 30, 2021

Primary Completion Date

March 28, 2022

Study Completion Date

March 28, 2022

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

DBPR108 tablets

DBPR108 tablets, oral, once daily on Day 1 and Day 3-9 for a total of 8 doses.

Trial Locations (1)

100000

Beijing Anzhen Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY

NCT05146869 - A Single-dose and Multiple-dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of DBPR108 Tablets in Type 2 Diabetes Mellitus Patients | Biotech Hunter | Biotech Hunter